Literature DB >> 16275854

Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG.

Y Hatanaka1, S Hemmi, M B Morgan, M L Scheufele, G C Claussen, G I Wolfe, S J Oh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16275854     DOI： 10.1212/01.wnl.0000183145.91579.74

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  22 in total

Review 1.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

Review 4.  Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies.

Authors:  Sanjeev Rajakulendran; Stuart Viegas; Jennifer Spillane; Robin S Howard
Journal:  J Neurol       Date:  2012-09-07       Impact factor: 4.849

Review 5.  Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

Authors:  Rebecca L Hurst; Clifton L Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

6.  Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182

Review 7.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

Authors:  Agnes van Sonderen; Paul W Wirtz; Jan J G M Verschuuren; Maarten J Titulaer
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.